



METHODOLOGY

Open Access

Effective knowledge management in translational medicine

Sándor Szalma^{1*}, Venkata Koka¹, Tatiana Khasanova², Eric D Perakslis³

Abstract

Background: The growing consensus that most valuable data source for biomedical discoveries is derived from human samples is clearly reflected in the growing number of translational medicine and translational sciences departments across pharma as well as academic and government supported initiatives such as Clinical and Translational Science Awards (CTSA) in the US and the Seventh Framework Programme (FP7) of EU with emphasis on translating research for human health.

Methods: The pharmaceutical companies of Johnson and Johnson have established translational and biomarker departments and implemented an effective knowledge management framework including building a data warehouse and the associated data mining applications. The implemented resource is built from open source systems such as i2b2 and GenePattern.

Results: The system has been deployed across multiple therapeutic areas within the pharmaceutical companies of Johnson and Johnsons and being used actively to integrate and mine internal and public data to support drug discovery and development decisions such as indication selection and trial design in a translational medicine setting. Our results show that the established system allows scientist to quickly re-validate hypotheses or generate new ones with the use of an intuitive graphical interface.

Conclusions: The implemented resource can serve as the basis of precompetitive sharing and mining of studies involving samples from human subjects thus enhancing our understanding of human biology and pathophysiology and ultimately leading to more effective treatment of diseases which represent unmet medical needs.

Background

The effective management of knowledge in translational research setting [1,2] is a major challenge and opportunity for pharmaceutical research and development companies. The wealth of data generated in experimental medicine studies and clinical trials can inform the quest for next generation drugs but only if all the data generated during those studies are appropriately collected, managed and shared. Some notable successes have been already achieved.

Merck has developed a system which enables sharing of human subject data in oncology trials with the Moffit Cancer Center and Research Institute [3]. This system is built from proprietary and commercial components such as Microsoft BizTalk business process server,

Tibco and Biofortis LabMatrix application and does not address any data sharing issues outside of the two institutions.

There is a growing set of data being deposited in NCBI GEO [4], EBI Array Express [5], Stanford Microarray Database [6] and the caGRID infrastructure [7] which is derived from gene expression experiments on tissue samples collected from clinical setting. Many of those are from either drug discovery or biomarker discovery projects. In particular, Johnson & Johnson through its subsidiaries have contributed such data sets into GEO and Array Express.

These databases enforce standards for some of the elements of the experimental metadata [8]. In general, the phenotype annotations in the metadata are not required to follow standard dictionaries or vocabularies. That can cause considerable issues as it was recently demonstrated [9] and described in the following example.

* Correspondence: sszalma@its.jnj.com

¹Centocor R&D, Inc. 3210 Merryfield Row, San Diego, CA 92130, USA

These databases allow bioinformaticians to download the normalized data and carry out further analysis. The typical setting for such analyses that the scientist poses some hypotheses with respect to the phenotype and the informatician then needs to discern those phenotypes from the semi-structured data and correlate it with genotype in a sub-optimal process. In some cases the decoding and interpretation of the different phenotype can lead to serious mistakes such as the case recently discovered when multiple publications interpreted normal samples as cancer samples leading to erroneous conclusions [9].

The computational experiments can lead to validation of the primary findings or to novel discoveries such as in the case of meta-analysis of multiple datasets. The burden of deconvoluting the phenotypes from source files downloaded from these primary sources and coding them in a standard to enable large-scale meta-analyses makes these types of discoveries very costly and in fact quite rare [10-13].

Data curation is a way to tackle some of these issues. Typically, derived databases of omics experiments are curated to create comparisons for specialized mining with specific questions in mind. For example, there are multiple resources being developed to integrate and analyze gene expression and other omic data and create contrasts (A vs. B comparisons) or signatures [14,15]. The limitation of these resources is that they strive to answer specific questions and thus limit in-depth exploration of the data.

The treasure trove of high-content data derived from human samples can be much more effectively mined if standard dictionaries applied to all these studies and each subject's clinical and the associated sample's genomics data is stored and analyzed through a system which enables efficient access and mining. An example of such standardized infrastructure and potential for pre-competitive sharing is presented below.

Methods

Johnson & Johnson has invested in translational research by establishing within its pharmaceutical R&D division a set of translational and biomarker groups and focusing also on the management and mining of the data emanating from integrative settings crossing the drug discovery and development stages. One of the deliverables of this enhanced governance structure was the development of a translational medicine informatics infrastructure. This infrastructure is a combination of dedicated people, robust processes and informatics solution - transSMART.

We have established a strong cooperation across the R&D of the pharmaceutical companies of Johnson & Johnson and an open innovation partnerships with the



Cancer Institute of New Jersey and St. Jude Children's Research Hospital [16]. The R&D Informatics and IT group works in close collaboration with discovery biologists, pharmacologists, translational and biomarker scientist, clinicians and compound development team leaders with a goal to develop a system which enables democratic access to all the data generated during target validation, biomarker discovery, mechanism of action, preclinical and translational studies and clinical development.

An important aspect of successfully introducing a paradigm shift within a large pharmaceutical organization is change management. From the start we have recruited biologists, pharmacologists and physicians from various therapeutic areas to help champion the adaptation of the newly developed translational infrastructure but also to guide us through the development of the application in an agile environment.

The translational medicine data warehouse - transMART - was developed in partnership with Recombinant Data Corporation (Fig. 1) and detailed description of the system was reported previously [17]. Here we give an overview of the salient points of the application. In short, the data warehouse contains structured data from internal clinical trials and experimental medical studies and a set of public sources. The data modalities include clinical data and aligned high-content biomarker data such as gene expression profiles, genotypes, serum protein panels, metabolomics and proteomics data.

Data is stored in an Oracle 11 database which is fully auditable. We selected a set of open-source components to assemble the application in contrast to the strategy followed by Merck. A user interface providing a biological concept search of analyzed data sets and an i2b2 [18] based comparison engine for subject level clinical data were constructed in Java using Grails. Advanced pipelines were established for launching analytical workflows of gene and protein expression and SNP data between cohorts to present comparisons in Gene Pattern [19] and Haploview [20]. The solution is hosted on Amazon Elastic Compute Cloud and strict security policy is enforced. Authentication as well as role-based authorization model is implemented throughout the application so that study level permissions are enabled.

Clinical trial and experimental medicine study data sets were transformed by curators and ETL (Extract, Transform, Load) developers into an i2b2 [21] EAV (Entity-Attribute-Value model) structure and a standardized ontology based on CDISC SDTM (Clinical Data Interchange Standards Consortium - Study Data Tabulation Model) [22] was applied. Currently, the system contains a growing number of curated internal studies - at the time of writing it is 30 across immunology, oncology, cardiovascular and CNS therapeutics areas.



The same process was utilized for multiple public expression experiment from samples of human origin downloaded from GEO, Array Express or other public repositories (see the flow chart and example in Figure 2a, b). The gene expression data was normalized using a standard protocol if the original raw files were available or the intensities were downloaded from the source systems. The phenotypes were manually turned into CDISC SDTM concepts which then were stored in a standardized hierarchy accessible through the familiar explorer paradigm. Here each concept can be selected and used for constructing a query. At the time of writing this article there are 30 such data sets in tranSMART.

Results

In the following we show some sample analyses which can be done very efficiently with the tranSMART system once appropriate curation of public data [23] takes place (Fig. 3a-j). With a simple drag-and-drop cohort selection paradigm different dimensions of the data can be

selected and the system can run queries in mere seconds to generate analyses which can reproduce original results such as *MAGEA3* differential expression between basal cell carcinoma and metastatic carcinoma samples shown in Figures 3a-c.

Interestingly, comparing basal cell carcinoma samples with metastatic carcinoma samples using the ComparativeMarkerSelection algorithm [24] built into GenePattern highlights the *HSD17B11* gene as the highest scored gene which is consistently upregulated in the metastatic samples (Figure 4d, e) supported by the sophisticated statistical algorithms built into the GenePattern application (e.g.: false discovery rate estimation by the Benjamini and Hochberg procedure [25]). Searching for evidence in PubMed for association between *HSD17B11* and melanoma brings up no hits but is associated with seminal vesicle invasion in prostate cancer [26]. TranSMART system also enables doing a thorough search across multiple databases for evidence of a gene's involvement in biological processes and experiments as illustrated in Figure 5.




Figure 3 Hypothesis re-validation. Original findings can be re-validated by using a simple drag-and-drop cohort selection and analysis paradigm such as visualizing *MAGEA3* differential expression between basal cell carcinoma and metastatic carcinoma samples (a-c).

Novel hypotheses can be also tested in a straightforward manner as it is illustrated in Figures 6a, b. Here the suggested association of *cyclin D1* with progression from benign to malignant stages [27] is illustrated using k-means clustering as one of the clustering methods implemented through connection with GenePattern [19]. While the expression levels of *cyclin D1* increase from benign to malignant, in metastatic melanomas the expression level decreases [27] which in turn demonstrated by the clustering method clearly delineating multiple subgroups of samples in the presumably homogenous metastatic melanoma cohort.

Queries can use Boolean operators such as OR and AND as illustrated in Figures 7a, b where the first

cohort contains samples from tissues from subjects with primary melanoma, or basal cell carcinoma or squamous cell carcinoma and the second cohort consist of samples from tissues from subject with metastatic melanoma. The example shows the resulting heatmap of expression data of a particular gene (*CFL2*) of this complex query. In subset one (denoted by S1_... sample ids) most of the samples have low expression of the gene of interest (denoted by blue color) whereas in subset two (denoted by S2_... sample ids) most of the samples have high expression of the gene of interest (denoted by red color).

Cross-study meta-analyses are also available in the application (Figure 8a, b). In this example two gene





Figure 6 New hypothesis testing. New hypotheses can be tested - the role of *cyclin D1* in metastatic melanoma in single cohort using k-means clustering (a,b).



expression datasets from Veridex - from colorectal and lung cancer tissue samples [9] - were previously processed, normalized and uploaded into transSMART. Both sets of tissues were analyzed using the same Affymetrix U133 GeneChip platform [9]. The transSMART system then enables one to construct a query where the gene expression values of the two sets of tissue samples can be aligned and analyzed. As an example we show that a simple k-means clustering as implemented in GenePattern using the *EGFR* gene with $k = 2$ can stratify the subjects into high and low expressors.


Discussion

The transSMART system allows clinicians, translational scientists and discovery biologists to interrogate aligned phenotype/genotype data to enable better clinical trial design or to stratify disease into molecular subtypes with great efficiency. Initial successes of applying this system point towards the high value of translational data in proposing indications for drugs with new

mechanism of actions [J. Smart, personal communication] and selecting biomarkers for stratified medicine.

The system has been in wide use across multiple therapeutic areas within the pharmaceutical companies of Johnson and Johnson. Comparing biological processes and pathways between multiple data sets from related disease or even across multiple therapeutic areas is an important benefit of such a system. Through the examples presented above we have shown that the transSMART system allows scientist to quickly re-validate hypotheses or generate new ones with the use of an intuitive graphical user interface. The use cases supported by transSMART have been developed in close collaboration with key users and the solution was built from many open source systems making the adaptation of the system straightforward.

We have implemented a fine-grained, role-based authorization model throughout the application so that study level permissions are enabled and can be controlled by the study owners. During curation the study



owners are actively involved in reviewing and approving the loading and standardization of the data from their studies. This approach greatly enhanced the cooperation of the study owners and the ultimate success of the data warehouse.

Conclusions

A well-constructed system can enable scientist to test but also generate new hypotheses using well-curated, high-content translational medicine data leading to deeper understanding of various biological processes and eventually helping to develop better treatment options.

Active curation and enterprise data governance have proven to be critical aspects of success. The capability of the system to query both internal and public data and that during the development and implementation full organizational alignment was ensured turned out to be crucial.

Because large part of tranSMART is built from open source systems it is much more amenable for being

shared with academic institutions in a pre-competitive setting enabling collaborations aimed at developing deeper understanding disease biology.

The tranSMART system is under active development including active curation of additional studies, implementing new modalities and adding novel workflows. Future development may include connection to the internal biobank. By the established system and the robust processes our research and development organization can now effectively manage not just the complex and multimodal data but can also unlock the potential of the data by transforming it into actionable knowledge.

Acknowledgements

We thank Daniel Housman, Jinlei Liu and Joseph Adler from Recombinant Data Corporation for their work in implementing the system. We are also thankful to reviewers for helpful suggestions.

Author details

¹Centocor R&D, Inc. 3210 Merryfield Row, San Diego, CA 92130, USA.

²GeneGo, 169 Saxony Road, #104, Encinitas, CA 92024, USA. ³Centocor R&D, Inc. 145 King of Prussia Rd., Radnor, PA 19087, USA.

Authors' contributions

SS and EP conceived and designed the study. VK and TK assisted with the experiments. SS drafted the manuscript. All authors read and proofed the final manuscript.

Competing interests

SS, VK and EP are employees of Johnson and Johnson.

Received: 6 April 2010 Accepted: 19 July 2010 Published: 19 July 2010

References

1. CTSA: [http://www.ctsaweb.org/].
2. FP7: [http://ec.europa.eu/research/fp7/index_en.cfm?pg=health].
3. BioIT World: [http://www.bio-itworld.com/BioIT_Article.aspx?id=49382].
4. Edgar R, Domrachev M, Lash AE: **Gene Expression Omnibus: NCBI gene expression and hybridization array data repository.** *Nucleic Acids Res* 2002, **30**:207-10.
5. Parkinson H, *et al*: **ArrayExpress update—from an archive of functional genomics experiments to the atlas of gene expression.** *Nucleic Acids Res* 2009, **37**:D868-72.
6. Hubble J, *et al*: **Implementation of GenePattern within the Stanford Microarray Database.** *Nucleic Acids Res* 2009, **37**:D898-901.
7. Saltz J, *et al*: **caGrid: design and implementation of the core architecture of the cancer biomedical informatics grid.** *Bioinformatics* 2006, **22**:1910-6.
8. MIAME: [http://www.mged.org/Workgroups/MIAME/miame.html].
9. Irgon J, Huang CC, Zhang Y, Talantov D, Bhanot G, Szalma S: **Robust multi-tissue gene panel for cancer detection.** *BMC Cancer* 2010, **10**:319.
10. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM: **Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression.** *Proc Natl Acad Sci USA* 2004, **101**:9309-9314.
11. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA Jr, Marks JR, Dressman HK, West M, Nevins JR: **Oncogenic pathway signatures in human cancers as a guide to targeted therapies.** *Nature* 2006, **439**:353-357.
12. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR: **The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease.** *Science* 2006, **313**:1929-1935.
13. Dudley JT, Tibshirani R, Deshpande T, Butte AJ: **Disease signatures are robust across tissues and experiment.** *Molecular Systems Biology* 2009, **5**:307.
14. Chen R, Mallelwar R, Thosar A, Venkatasubrahmanyam S, Butte AJ: **GeneChaser: identifying all biological and clinical conditions in which genes of interest are differentially expressed.** *BMC Bioinformatics* 2008, **9**:548.
15. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM: **Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.** *Neoplasia* 2007, **9**:166-80.
16. Perakslis ED, Van Dam J, Szalma S: **How informatics can potentiate pre-competitive open source collaboration to jump-start drug discovery and development.** *Clin Pharma Therap* 2010, **87**:614-6.
17. Szalma S, Housman D, Adler J, Liu J, Leibfreid G, Perakslis ED: **Successfully Building a System for Enabling Translational Research.** *JAMIA* 2010, submitted.
18. i2b2: [http://www.i2b2.org].
19. Reich M, *et al*: **GenePattern 2.0.** *Nature Genetics* 2006, **38**:500-1.
20. Barrett JC, Fry B, Maller J, Daly MJ: **Haploview: analysis and visualization of LD and haplotype maps.** *Bioinformatics* 2005, **21**:263-5.
21. Murphy SN, Mendis M, Hackett K, Kuttan R, Pan W, Phillips LC, Gainer V, Berkowicz D, Glaser JP, Kohane I, Chueh HC: **Architecture of the open-source clinical research chart from Informatics for Integrating Biology and the Bedside.** *AMIA Annu Symp Proc* 2007, **548**-52.
22. CDISC: [http://www.cdisc.org/sdtm].
23. Riker AJ, *et al*: **The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.** *BMC Med Genomics* 2008, **1**:13.
24. Gould J, Getz G, Monti S, Reich M, Mesirov JP: **Comparative gene marker selection suite.** *Bioinformatics* 2006, **22**:1924-5.
25. Benjamini Y, Hochberg Y: **Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing.** *Journal of the Royal Statistical Society. Series B* 1995, **57**:289-300.
26. Nakamura Y, Suzuki T, Arai Y, Sasano H: **17beta-hydroxysteroid dehydrogenase type 11 (Pan1b) expression in human prostate cancer.** *Neoplasma* 2009, **56**:317-20.
27. Karim RZ, Li W, Sanki A, Colman MH, Yang YH, Thompson JF, Scolyer RA: **Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors.** *Int J Surg Pathol* 2009, **17**:361-7.

doi:10.1186/1479-5876-8-68

Cite this article as: Szalma *et al*: Effective knowledge management in translational medicine. *Journal of Translational Medicine* 2010 **8**:68.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

